A phase 1b/2a trial to investigate safety and efficacy of tesevatinib for the treatment of Autosomal Recessive Polycystic Kidney disease (ARPKD) in newborns

Trial Profile

A phase 1b/2a trial to investigate safety and efficacy of tesevatinib for the treatment of Autosomal Recessive Polycystic Kidney disease (ARPKD) in newborns

Planning
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Tesevatinib (Primary)
  • Indications Autosomal recessive polycystic kidney disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Aug 2017 According to a Kadmon Corporation media release, the company expects to initiate this trial in third quarter of 2017.
    • 22 Mar 2017 According to a Kadmon Corporation media release, the company anticipates to initiate this study in the second quarter of 2017.
    • 19 Nov 2016 According to a Kadmon Corporation media release, the company anticipates to initiate this study in the year 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top